PHARMA NORGE AS
Score · fiscal year 2025
58of 100
How to read this: the company is ahead of 66 % of small companies in the same sector in 2025. What does this mean?
Rank: 13,362 of 38,671 · Handel
Profile
Lion · Leader
High profitability, high solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 77 and solidity 59 out of 100 among small companies in the same sector in 2025. Methodology
Against the sector
PHARMA NORGE AS is 8 points above the median for small companies in the same sector in 2025.
Median score 50 among 36,111 companies.
Against small companies in the same sector in 2025: operating margin 11.9% (median 2.5%) and equity ratio 55.7% (median 38.3%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 63 MNOK | 3 MNOK |
| Operating margin | 11.9% | 2.5% |
| Profit margin | 13.1% | 2.2% |
| Return on assets | 16.4% | 4.0% |
| Equity ratio | 55.7% | 38.3% |
| Debt-to-equity | 0.80 | 0.99 |
| Current ratio | 0.63 | 1.70 |
| Revenue growth | 14.4% | 3.5% |
| Revenue per employee | 2.63 MNOK | 1.62 MNOK |
The median and “ahead of” refer to small companies in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 58, PHARMA NORGE AS does better than 66% of small companies in the same sector (36,580 companies) in 2025.
Score 2023–2025
- PHARMA NORGE AS
- Median: small companies in the same sector
PHARMA NORGE AS has a score of 58 for 2025, rank 13,362 of 38,671 in the sector.
Strongest: Profitability: percentile 77 against peers, operating margin 11.9% against a median of 2.5%. Growth: percentile 70 against peers, revenue growth 14.4% against a median of 3.5%.
Weakest: Liquidity: percentile 15 against peers, current ratio 0.63 against a median of 1.70.
Worth a closer look
- Consider strengthening liquidity: current liabilities are 1.6 times current assets. Based on: current ratio 0.63 (median 1.70).
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
What the numbers say
PHARMA NORGE AS had an operating margin of 11.9% and an equity ratio of 55.7% in 2025, and ranks 13,362 of 38,671 in Handel.
From 2024 to 2025: the operating margin fell from 28.0% to 11.9% and the equity ratio fell from 73.5% to 55.7%.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 29 MNOK and 81 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 81 MNOK |
| EV/EBIT | 8.0 | 60 MNOK |
| P/B | 1.0 | 29 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
- watch
Consider strengthening liquidity: current liabilities are 1.6 times current assets.
Based on: Current ratio 0.63 (median 1.70).
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 1.6% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2017, the sector's weakest year, for this company.
The sector's weakest year was 2017, with a median operating margin of −65.6%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 77 | weight 30% |
|---|---|---|
| Solidity | 59 | weight 25% |
| Liquidity | 15 | weight 15% |
| Growth | 70 | weight 15% |
| Consistency | 46 | weight 15% |
Durability: 67 (average over 3 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is PHARMA NORGE AS?
The operating margin was 11.9% in 2025, against a median of 2.5% among small companies in the same sector. Return on assets was 16.4%.
How solid is PHARMA NORGE AS?
The equity ratio was 55.7% in 2025 (median 38.3%). Debt-to-equity was 0.80 (median 0.99).
What is the liquidity of PHARMA NORGE AS like?
The current ratio was 0.63 in 2025 (median 1.70). Current assets did not cover current liabilities.
How does PHARMA NORGE AS compare in Handel?
PHARMA NORGE AS ranks 13,362 of 38,671 in Handel for 2025. Among companies of the same size (small companies) it ranks 12,551 of 36,580. Revenue changed by 14.4% from the year before.
Group accounts
The company is registered as part of a group, but we have no group accounts for it. Group accounts are filed by the parent company, and open data does not say which company that is.
Read the figures with care: a company in a group can look strong because of group contributions, or weak because dividends go up to the parent. The figures are indications, not the full picture.
We do not show the group structure, because open data does not say who owns whom.
From the Central Coordinating Register
- Org. no.
- 919821590
- Legal form
- AS · part of a group
- Sector
- Handel (47.270)
- Size tier
- small
- Employees
- 24 registered 10 September 2026
- Founded
- 1 October 2017 9 years in operation
- Share capital
- 0.29 MNOK
- Business address
- Sørvåg, 8432 ALSVÅG (ØKSNES)
- Municipality
- Øksnes rank 11–18 of 18 in KOSTRA group 2
- Latest accounts filed
- 2025
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
- Chief executive
- Rune Meyer
- Chair of the board
- Thomas Kristoffer Storvestre
- Auditor
- REVICOM AS
- Accountant
- BOKHOLDERIET AS
- Accountant
- ØKORÅD ØKSNES AS
Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 26 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 68 | 74 | 58 | |
| Rank | 6,937 | 2,969 | 13,362 | |
| Operating margin | 20.7% | 28.0% | 11.9% | |
| Return on assets | 21.7% | 33.0% | 16.4% | |
| Equity ratio | 80.4% | 73.5% | 55.7% | |
| Current ratio | 1.15 | 1.85 | 0.63 | |
| Revenue growth | – | 36.3% | 14.4% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 40.5 MNOK | 55.2 MNOK | 63.1 MNOK |
| Operating profit | 8.4 MNOK | 15.5 MNOK | 7.5 MNOK |
| Profit before tax | 8.7 MNOK | 15.4 MNOK | 8.2 MNOK |
| Net profit | 6.8 MNOK | 14.2 MNOK | 8.1 MNOK |
| Financial expenses | 0.0 MNOK | 0.6 MNOK | 0.4 MNOK |
| Total assets | 40.4 MNOK | 48.3 MNOK | 52.6 MNOK |
| Current assets | 9.1 MNOK | 21.4 MNOK | 14.7 MNOK |
| Equity | 32.5 MNOK | 35.5 MNOK | 29.3 MNOK |
| Retained earnings | 9.4 MNOK | 12.4 MNOK | 6.2 MNOK |
| Total liabilities | 7.9 MNOK | 12.8 MNOK | 23.3 MNOK |
| Current liabilities | 7.9 MNOK | 11.6 MNOK | 23.3 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 26 October 2026, accounts id 6993760.
Further
Similar companies
- TURISTFORUM A. JOHANNESSEN EFT. AS index 58, rank 13,359 · compare
- EXTRA LEKER LARVIK AS index 58, rank 13,360 · compare
- EAGLE TRADING AS index 58, rank 13,361 · compare
- JOTO INVESTMENTS AS index 58, rank 13,363 · compare
- NORA FOODS AS index 58, rank 13,364 · compare